Drug Trial Radar · NCT02666053
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jan 27, 2016
Primary completion
Feb 22, 2016
Study completion Feb 22, 2016
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jan 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate the effect of high fat meal and increased gastric pH on BMS-663068 bioavailability
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068Drug
BMS-663068
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Days 1-12
- Area under the plasma concentration-time curve from time zero extrapolated to infinity, AUC (INF)Time frame: Days 1-12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.